ArticleJournal of neurology2026
Real-world safety of satralizumab in neuromyelitis optica spectrum disorder: a FAERS-based risk stratification study.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundSatralizumab, an interleukin-6 receptor monoclonal antibody, is an established therapy for neuromyelitis optica spectrum disorder (NMOSD). While randomized trials have demonstrated their efficacy and short-term safety, real-world data characterizing report-level associations and severe adverse outcomes remain limited.
methodsWe performed a retrospective pharmacovigilance study using the U.S. FDA Adverse Event Reporting System (FAERS) from Q1 2004 to Q3 2025. Disproportionality analyses (reporting odds ratios [RORs], information components [ICs]), subgroup analyses, co-medication analysis, time-to-onset evaluation, and multivariable logistic regression for most severe outcomes (death/life-threatening events) were conducted.
resultsAmong 1174 satralizumab-related reports, infections were the most prominent signals, with key signals including atypical mycobacterial infection (ROR 109.24, 95% CI 51.92-229.82; IC 6.76, IC025 1.88), pneumonia pneumococcal (ROR 41.51, 95% CI 13.36-128.94; IC 5.37, IC025 0.45), and pyelonephritis (ROR 40.80, 95% CI 25.32-65.75; IC 5.34, IC025 2.98). Forty unlabeled events (e.g., lymphocyte count decrease [ROR 18.52, 95% CI 11.33-30.27]) were identified. Concomitant corticosteroid use was associated with increased reporting of infectious and hepatic adverse events. Among 827 reports with complete demographic data, 72 were classified as most severe. Factors associated with severe outcome reports included age ≥ 65 years (adjusted odds ratio [OR] 3.85, 95% CI 2.22-6.69), male sex (adjusted OR 2.23, 95% CI 1.20-4.15), and septic shock (adjusted OR 7.88, 95% CI 2.48-25.09). Median time to onset was 97 days (interquartile range 15-291 days), with early and late peaks.
conclusionsThis real-world study highlights clinically relevant safety signals of satralizumab in NMOSD, identifies vulnerable patient subgroups, and supports risk-adapted monitoring strategies in neurological practice.
Indexed as
Identifiers
41843239What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.